Compare CXT & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXT | CELC |
|---|---|---|
| Founded | 1855 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.1B |
| IPO Year | 1994 | 2017 |
| Metric | CXT | CELC |
|---|---|---|
| Price | $41.51 | $113.10 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $76.75 | ★ $106.63 |
| AVG Volume (30 Days) | ★ 688.2K | 526.7K |
| Earning Date | 05-06-2026 | 03-25-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $3,374,900,000.00 | N/A |
| Revenue This Year | $5.75 | N/A |
| Revenue Next Year | $4.22 | N/A |
| P/E Ratio | $16.57 | ★ N/A |
| Revenue Growth | ★ 6.13 | N/A |
| 52 Week Low | $41.43 | $7.58 |
| 52 Week High | $69.00 | $120.32 |
| Indicator | CXT | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 21.93 | 53.84 |
| Support Level | N/A | $97.75 |
| Resistance Level | $61.93 | $117.27 |
| Average True Range (ATR) | 1.50 | 5.38 |
| MACD | -0.52 | -0.07 |
| Stochastic Oscillator | 10.32 | 58.88 |
Crane NXT Co is a industrial technology company that provides proprietary and trusted technology solutions to secure, detect, and authenticate what matters to its customers. It is a pioneer in proprietary micro-optics technology for securing physical products, and its sophisticated electronic equipment and associated software leverages proprietary core capabilities with detection and sensing technologies. The company operates in two segments which are Crane Payment Innovations (CPI) and Security and Authentication Technologies.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.